.Kaufmann, P., Pariser, A. R. & Austin, C. Coming from clinical exploration to procedures for rare diseasesu00e2 $" the perspective coming from the National Facility for Accelerating Translational Sciencesu00e2 $" Office of Rare Diseases Study. Orphanet J. Rare Dis. Thirteen, 196 (2018 ). Articleu00c2.PubMedu00c2.Google.com Scholaru00c2.Crooke, S. T. A call to arms versus ultra-rare conditions. Nat. Biotechnol. 39, 671u00e2 $ "677 (2021 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Vockley, J. et al. The evolving part of clinical geneticists in the time of gene therapy: a necessity to prepare. Genet. Medication. 25, 100022 (2023 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Kim, J. et al. Patient-customized oligonucleotide treatment for an unusual genetic disease. N. Engl. J. Med. 381, 1644u00e2 $ "1652 (2019 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Kim, J. et al. A platform for individual splice-switching oligonucleotide therapy. Type 619, 828u00e2 $ "836 (2023 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Lima, W. F. et cetera. Individual RNase H1 evaluates in between refined varieties in the construct of the heteroduplex substrate. Mol. Pharmacol. 71, 83u00e2 $ "91 (2007 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Crooke, S. T., Baker, B. F., Crooke, R. M. & Liang, X.-H. Antisense technology: an outline as well as syllabus. Nat. Rev. Drug Discov. 20, 427u00e2 $ "453 (2021 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Lee, J.-R. et cetera. De novo mutations in the electric motor domain name of KIF1A trigger intellectual problems, abnormal paraparesis, axonal neuropathy, and also cerebellar degeneration. Hum. Mutat. 36, 69u00e2 $ "78 (2015 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Boyle, L. et al. Genotype and flaws in microtubule-based motility connect with scientific severeness in KIF1A-associated neurological disorder. HGG Adv. 2, 100026 (2021 ). CASu00c2.PubMedu00c2.Google Scholaru00c2.Kondo, M., Takei, Y. & Hirokawa, N. Electric motor protein KIF1A is important for hippocampal synaptogenesis and learning improvement in an enriched setting. Nerve cell 73, 743u00e2 $ "757 (2012 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Guo, Y. et cetera. An uncommon KIF1A missense mutation improves synaptic functionality and also improves confiscation task. Front end. Genet. 11, 61 (2020 ). Articleu00c2.CASu00c2.PubMedu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Kaur, S. et al. Expansion of the phenotypic range of de novo missense alternatives in kinesin relative 1A (KIF1A). Hum. Mutat. 41, 1761u00e2 $ "1774 (2020 ). Articleu00c2.CASu00c2.PubMedu00c2.PubMed Centralu00c2.Google Scholaru00c2.Canivez, G. L. & McGill, R. J. Element design of the Differential Capacity Scales-Second Edition: exploratory and also hierarchical element evaluations with the center subtests. Psychol. Assess. 28, 1475u00e2 $ "1488 (2016 ). Articleu00c2.PubMedu00c2.Google.com Scholaru00c2.Epstein, A. et al. Web content verification of the lifestyle inventoryu00e2 $" impairment. Childcare Health Dev. 45, 654u00e2 $ "659 (2019 ). Articleu00c2.PubMedu00c2.Google Scholaru00c2.Lek, M. et cetera. Study of protein-coding genetic variation in 60,706 humans. Attribute 536, 285u00e2 $ "291 (2016 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.IND Submissions for Individualized Antisense Oligonucleotide Medicine Products for Significantly Incapacitating or even Severe Ailments: Clinical Referrals (United States Fda, 2022) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-submissions-individualized-antisense-oligonucleotide-drug-products-severely-debilitating-or-lifeIND Submissions for Individual Antisense Oligonucleotide Medication Products: Administrative and Procedural Recommendations Support for Sponsor-Investigators (US Fda, 2021) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-submissions-individualized-antisense-oligonucleotide-drug-products-administrative-and-proceduralInvestigational New Medicine Application Articles for Customized Antisense Oligonucleotide Medication Products for Drastically Devastating or Serious Health Conditions: Chemistry, Manufacturing, and Controls Recommendations, Support for Sponsor-Investigators (US Fda, 2022) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-new-drug-application-submissions-individualized-antisense-oligonucleotide-drugNonclinical Screening of Individualized Antisense Oligonucleotide Medicine Products for Drastically Incapacitating or Severe Diseases Support for Sponsor-Investigators (US Food and Drug Administration, 2021) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-testing-individualized-antisense-oligonucleotide-drug-products-severely-debilitating-or.